---
title: "Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year"
description: "In 2026, the business expansion transactions of China's innovative drugs continued to heat up, with 44 external licensing transactions occurring within the year, totaling over USD 53 billion, with an "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276961831.md"
published_at: "2026-02-26T00:48:55.000Z"
---

# Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year

> In 2026, the business expansion transactions of China's innovative drugs continued to heat up, with 44 external licensing transactions occurring within the year, totaling over USD 53 billion, with an upfront payment of approximately USD 3.123 billion

In 2026, China's innovative drug outbound business development (BD) transactions continue to heat up and show strong momentum. According to the NextPharma database, as of February 25, there have been 44 outbound licensing (license-out) transactions involving Chinese innovative drugs this year, with an upfront payment of approximately USD 3.123 billion and a total amount reaching USD 53.276 billion. (Securities Daily)

### Related Stocks

- [159102.CN - Huaan Hang Seng Biotech ETF](https://longbridge.com/en/quote/159102.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [159839.CN - China Universal CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159839.CN.md)
- [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md)
- [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [513280.CN - China Universal Hang Seng Biotechnology Technology ETF(QDII)](https://longbridge.com/en/quote/513280.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 中國的九源基因正在尋求 Wegovy 生物類似藥的批准 | 九源基因生物醫藥已申請在中國銷售其 Wegovy 的生物仿製藥版本，正值關鍵專利到期之前。該公司報告稱，其三期臨牀試驗顯示，吉可沁在安全性和減重效果上與 Wegovy 具有臨牀等效性。九源還在尋求 Ozempic 的生物仿製藥版本的批准，旨 | [Link](https://longbridge.com/en/news/276994337.md) |
| 上海復宏漢霖在中國啓動 HLX22 聯合 HLX87 治療 HER2 陽性轉移性乳腺癌的二期/三期試驗，首位患者已接受治療 | 上海復宏漢霖生物科技股份有限公司已在中國啓動 HLX22 與 HLX87 聯合用作 HER2 陽性轉移性乳腺癌的一線治療的 2/3 期臨牀試驗。該試驗涉及將患者隨機分配接受不同的治療組合，主要終點關注客觀緩解率和無進展生存期。值得注意的是， | [Link](https://longbridge.com/en/news/277213924.md) |
| 君實生物 2025 財年的總營業收入為 25 億人民幣，同比增長 28.2% | 君實生物公佈了 2025 財年的初步業績，總營業收入為 25 億元人民幣，同比增長 28.2%。公司面臨 9.98 億元人民幣的營業虧損，總虧損為 10 億元人民幣，歸屬於股東的淨虧損為 8.74 億元人民幣。其核心產品託瑞帕姆在國內的銷售 | [Link](https://longbridge.com/en/news/277189371.md) |
| Radence 宣佈將參加 TD Cowen 第三屆年度 Glowing Ahead 峯會，主題為美麗的演變與長壽作為奢侈品 | Radence，一家禮賓科學的先驅，宣佈首席執行官 David Medeveff 將參加 2026 年 2 月 25 日舉行的 TD Cowen 第三屆 “光明前景” 峯會。Medeveff 將討論 “定義長壽：健康科學”，重點介紹個性化健 | [Link](https://longbridge.com/en/news/276920272.md) |
| Nuvia Dental Implant Center 被 BizTech Outlook 評選為 2026 年十大值得關注的公司之一 | Nuvia Dental Implant Center 被 BizTech Outlook 評選為 “2026 年十大值得關注公司” 之一，因其在全口牙種植方面的創新方法。該中心強調速度、安全和以患者為中心的護理，使患者在手術後僅需 24  | [Link](https://longbridge.com/en/news/277089366.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.